Inflammation-driven activation of JAK/STAT signaling reversibly accelerates acute myeloid leukemia in vitro
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inflammation-driven activation of JAK/STAT signaling reversibly accelerates acute myeloid leukemia in vitro
Authors
Keywords
-
Journal
Blood Advances
Volume 4, Issue 13, Pages 3000-3010
Publisher
American Society of Hematology
Online
2020-07-02
DOI
10.1182/bloodadvances.2019001292
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Haematopoietic stem cell activity and interactions with the niche
- (2019) Sandra Pinho et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Inhibition of Endosteal Vascular Niche Remodeling Rescues Hematopoietic Stem Cell Loss in AML
- (2018) Delfim Duarte et al. Cell Stem Cell
- Impact of inflammation on early hematopoiesis and the microenvironment
- (2017) Hitoshi Takizawa et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
- (2017) C N Harrison et al. LEUKEMIA
- Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia
- (2017) Alyssa Carey et al. Cell Reports
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche
- (2016) Haobin Ye et al. Cell Stem Cell
- Mesenchymal Inflammation Drives Genotoxic Stress in Hematopoietic Stem Cells and Predicts Disease Evolution in Human Pre-leukemia
- (2016) Noemi A. Zambetti et al. Cell Stem Cell
- ROS homeostasis and metabolism: a dangerous liason in cancer cells
- (2016) E Panieri et al. Cell Death & Disease
- Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia
- (2015) S. L. Maude et al. BLOOD
- The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis
- (2015) M. Deininger et al. BLOOD
- JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications
- (2015) L. Springuel et al. HAEMATOLOGICA
- Neural Regulation of Hematopoiesis, Inflammation, and Cancer
- (2015) Maher Hanoun et al. NEURON
- JAK-STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response
- (2015) M. Kleppe et al. Cancer Discovery
- JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications
- (2015) L. Springuel et al. HAEMATOLOGICA
- Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL
- (2014) I. Appelmann et al. BLOOD
- Acute Myelogenous Leukemia-Induced Sympathetic Neuropathy Promotes Malignancy in an Altered Hematopoietic Stem Cell Niche
- (2014) Maher Hanoun et al. Cell Stem Cell
- Myelodysplastic Cells in Patients Reprogram Mesenchymal Stromal Cells to Establish a Transplantable Stem Cell Niche Disease Unit
- (2014) Hind Medyouf et al. Cell Stem Cell
- Myeloproliferative Neoplasia Remodels the Endosteal Bone Marrow Niche into a Self-Reinforcing Leukemic Niche
- (2013) Koen Schepers et al. Cell Stem Cell
- Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS
- (2012) L. Barreyro et al. BLOOD
- Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia
- (2012) Kathryn G. Roberts et al. CANCER CELL
- The JAK2 46/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection?
- (2011) S. Hermouet et al. HAEMATOLOGICA
- Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
- (2011) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
- (2011) Alfonso Quintás-Cardama et al. NATURE REVIEWS DRUG DISCOVERY
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More